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ABSTRACT
BACKGROUND: Acute pancreatitis is a common complication of endoscopic
retrograde cholangiopancreatography (ERCP). The beneficial effects of pharmaco-
logic treatment of acute pancreatitis are unclear. Although the prophylactic use of
NSAIDs for the reduction of the risk for pancreatic injury after ERCP has been
assessed, the beneficial effects of NSAIDs on pancreatic injury are still being
debated.
OBJECTIVE: The aim of this study was to determine the effectiveness and
tolerability of NSAIDs in the prophylaxis of post-ERCP pancreatitis (PEP).
METHODS: MEDLINE Oanuary 1966-January 2009), EMBASE Oanuary 1966-
January 2009), and the Cochrane Central Register of Controlled Trials (Issue 1,2009)
were searched using the key terms: pancreatitis, post-ERCP pancreatitis, nonsteroidal anti-
inflammatory drugs, indomethacin, and diclofenac. The methods recommended by the
Cochrane Collaboration and the Quality of Reporting Meta-Analyses guideline were
used to conduct a systematic review and meta-analysis of randomized controlled trials
(RCTs) of NSAIDs in the prevention of PEP.
RESULTS: Four multinational RCTs were included in the meta-analysis (969 pa-
tients). The pooled odds ratio for NSAIDs for mild PEP was 0.69 (95% CI,
0.40-1.17; P = NS); moderate to severe PEP, 0.22 (95% CI, 0.05-1.01; P = 0.05);
PEP (pooled), 0.44 (95% CI, 0.21-0.93; P = 0.03); in high-risk patients, 0.49 (95% CI,
0.17-1.39; P = NS); and in low-risk patients, 0.29 (95% CI, 0.12-0.71; P = 0.006).
No evidence of publication bias was found.
CONCLUSION: Based on the findings from the present systematic review of
4 RCTs, NSAIDs were effective and well tolerated in the prevention of PEP, especially
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in low-risk patients. (Curr Ther Res Clin Exp. 2009;70:323-334) © 2009 Excerpta
Medica Inc.
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INTRODUCTION
Endoscopic retrograde pancreatography (ERCP) is an important procedure in the diag-
nosis and treatment of several biliary and pancreatic conditions. The prevention of
pancreatitis, a potential and sometimes serious complication ofERCP, is essentiaP The
incidence of post-ERCP pancreatitis (PEP) has varied between 2% and 30% in previ-
ously published case series, with an average occurrence of2% to 8%.2,3 Effective strate-
gies to prevent PEP remain elusive.4 Physicians should use prudent judgment in select-
ing patients with appropriate indications for ERCP. Prophylactic pancreatic stent
placement in high-risk cases continues to be the first line of PEP prevention.s
Drugs assessed for efficacy in the prevention of PEP have shown promise in single-
center studies, but not in larger, multicenter, randomized controlled trials (RCTs).3,4
Clinical studies of calcitonin,6 aprotinin,7 nifedipine,8 glucagon,9 and recombinant hu-
man interleukin-10 10,1l in patients scheduled to undergo ERCP have not reported a
significant decrease in the prevalence of post-ERCP hyperamylasemia or pancreatitis.
Six studies of the long-acting somatostatin analogue octreotide have reported conflicting
results. 12- 17 Meta-analyses of prospective RCTs of gabexate mesylate, corticosteroids,
and allopurinol have reported that these agents did not effectively prevent pancreatic
injury after ERCp' 18- 21 An inexpensive, easily administered drug with minimal adverse
effects and few contraindications is needed for the prevention of PEp'3
Although the pathogenesis of PEP is not clearly understood, it seems that the in-
flammatory response to pancreatic duct imaging and/or instrumentation plays a cru-
cial role. 22 Initial intracellular events result in pancreatic acinar cell damage, followed
by a local inflammatory response and the subsequent release of chemokines and
proinflammatory cytokines into the general circulation. 23 The severity of the attack
depends on the magnitude of the resultant systemic inflammatory response. 24 Theo-
retically, NSAIDs might prevent PEP by inhibiting prostaglandin synthesis and in-
terrupting the inflammatory cascade of pancreatitis. However, prospective studies of
the effectiveness of NSAIDs in the prophylaxis of PEP have generated contradictory
results. 2s- 28 The present meta-analysis aimed to systematically review all available
RCTs to provide information on the effectiveness and tolerability of NSAIDs in the
prophylaxis of PEP. All of the studies adopted the PEP diagnostic criteria proposed
by Cotton et al29 and adopted the suggestions of risk factors for PEP proposed by
Freeman and Guda. 2
MATERIALS AND METHODS
SELECTION CRITERIA
Database specialty personnel (A.-M.W.) searched MEDLINE Oanuary 1966-January
2009), EMBASE Oanuary 1966-January 2009), and the Cochrane Central Register of
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Controlled Trials (Issue 1,2009) using the key terms:pancreatitis,post-ERCP pancrea-
titis, nonsteroidal anti-inflammatory drugs, indomethacin, and diclofenac. Reference lists of
pertinent reviews and retrieved articles were checked to identify additional studies.
Data from poster presentations and consultations with several experts in the field
were also included.
The literature search was limited to prospective RCTs in patients aged ;;,18 years
who underwent ERCP and/or endoscopic sphincterotomy. Randomized comparisons
of NSAIDs and placebo were included, regardless of the initial time of treatment,
treatment duration, or dose and administration route of the drug. Trials of concurrent
interventions (including treating complications) were included if treatments were
administered equally to all intervention groups.
Studies were excluded if: the design was quasirandomized or nonrandomized,
patients with active acute pancreatitis were included, significant between-arm
differences were found (in trials of concurrent interventions), and/or the report
was repetitive (if> 1 version of a study was retrieved, only the most recent was
used).
Two of the investigators (M.-H.Z. and M.-B.M.) used these criteria to review each
article identified. Two end points were assessed: the prevalence of PEP and the
case:fatality ratio of PEP. Discrepancies in the assessment of some of the studies were
resolved through discussion between the investigators.
ASSESSMENT OF STUDY QUALITY
The quality of included reports was scored using the ]adad composite scale,30 which
assesses the descriptions of randomization, blinding, and withdrawals in clinical trials.31
The quality scale ranges from 0 to 5 points (::;;2 = poor quality; :2:3 = good quality).32
TOLERABILITY
The adverse events associated with NSAID use were assessed based on clinical
observation.
STATISTICAL ANALYSIS
Meta-analysis was performed by a biostatistician according to the recommen-
dations of the Cochrane Collaboration and the Quality of Reporting of Meta-
analyses guideline. 33 Pooled odds ratios (ORs) were calculated using the general
inverse variance fixed-effects model. Heterogeneity between studies was assessed
using the DerSimonian and Laird Q statis tical analysis. 34 If results were hetero-
geneous (P < 0.10), a random-effects model was employed using the DerSimonian
and Laird method. For studies in which the constructed 2 x 2 tables contained
cells with no events, a standard correction factor of 0.5 was added to each cell.
Pooled ORs were presented as standard plots with 95% CIs. Begg and Mazumdar's
proposed adjusted rank correlation test35 and Egger's linear regression test36 were
used to assess publication biases, which are reported using funnel plots. Statistical
analysis was performed using Intercooled Stata version 8.2 (StataCorp LP, College
Station, Texas).
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RESULTS
A total of 18 clinical trials and reports were identified, of which 4 qualified for inclu-
sion by the selection criteria (969 patients) (Figure 1).25-28 Searches of poster presen-
tations and consultations with several experts in the field yielded no additional
information. The main features and the quality Oadad) scores of the trials included in
the meta-analysis are shown in the table.
PREVALENCE OF POST-ERCP PANCREATITIS
PEP was reported in 95/969 patients (9.8%). Among these, 33 patients (6.8%)
were treated with NSAIDs; 62 (12.8%), placebo. There was a significant heterogene-
ity among these studies (X 2 = 6.89; degrees of freedom [df} = 3; P = 0.08). With
DerSimonian and Laird's analysis, the use of NSAIDs was significantly associated with
a reduction in the prevalence of PEP (pooled OR = 0.44; 95% CI, 0.21-0.93; P =
0.03) (Figure 2).
Severity of PEP (mild or moderate to severe) was not significantly associated with
prevalence (inverse variance fixed-effect pooled ORs: mild, 0.69 [95% CI, 0.40-1.17;
P = NS}; moderate to severe, 0.22 [95% CI, 0.05-1.01; P = 0.05}) (Figure 3). There
was no significant heterogeneity among mild cases (X 2 = 1.90; df = 2; P = NS) or
moderate to severe cases (X 2 = 1.48; df = 2; P = NS).
Risk for PEP (low or high) was significantly associated with prevalence (inverse
variance fixed-effect pooled ORs for low-risk patients, 0.29 [95% CI, 0.12-0.71; P =
0.006}; DL random-effect pooled OR for high-risk patients, 0.49 [95% CI, 0.17-
1.39; P = NS}) (Figures 4 and 5). Significant heterogeneity was found in the low-risk
cohort (X 2 = 8.44; df = 3; P = 0.04) but not in the high-risk cohort (X 2 = 0.58; df = 2;
P = NS).
CASE:FATALITY RATIO OF PEP
The case:fatality ratio of PEP was extracted from all 4 trials. 25- 28 No deaths
were reported in patients who received NSAIDs or placebo. All of the patients
were discharged in good health and reported a good quality of life in the follow-
up phases. However, all of the studies lacked data on death in the follow-up
phases.
PUBLICATION BIAS
Publication bias was assessed for all pooled ORs with CIs using Begg and Mazum-
dar's test,35 which is a scatter plot of the treatment effects estimated from individual
studies plotted on the x axis (OR) against the SE of the estimate shown on the y axis
(SE [log OR}). As shown in Figure 6, the findings from all of the studies were within
the 95% CI and were distributed around the y axis, suggesting a low likelihood of
publication bias (P = NS [Egger's test}).
TOLERABILITY
No adverse events were reported with NSAID use. None of the adverse events were
considered treatment related.
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MEDLINE (January 1966-January 2009)
EMBASE (January 1966-January 2009)
Cochrane Central Register of Controlled Trials
(Issue 1, 2009)
Potentially appropriate trials to be
included in meta-analysis (n = 18)
No additional studies were identified
from the reference lists of pertinent
reviews and retrieved articles
I Accessed trials (n = 18)
/
Randomized controlled trials
included in meta-analysis (n = 4)
Excluded (n = 14)
Abstract or data insufficient (6)
Difference in cointerventions (2)
Reviews or editorials (2)
Incorrect randomization (1)
Placebo group lacking (1)
Other (2)
Figure 1. Identification of eligible randomized controlled trials.
DISCUSSION
Pharmacotherapy has been widely studied in the prevention of PEP. Murray et al25
reported findings from a prospective, single-center, double-blind, RCT of rectal
diclofenac administered for PEP prevention immediately after ERCP. Of 220 patients,
110 received rectal diclofenac and 110 received an inactive vehicle (placebo). PEP oc-
curred in 6.4% of patients in the diclofenac group and in 15.5% of patients in the
placebo group (P = 0.049). Diclofenac was not found to be effective in a subgroup of
patients with sphincter of Oddi hypertension (diclofenac, 3/26 [l1.5%}; placebo,
4/27 [l4.8%}), the group at highest risk for PEP.
In a 2007 prospective, double-blind, randomized study, Sotoudehmanesh et al28
presented data on indomethacin administration for the prevention of PEP. Eligible
patients undergoing ERCP were randomly assigned to receive an indomethacin
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Table. Single-center, double-blind, randomized controlled trials of NSAIDs in the prevention of pancreatic injury after endoscopic
retrograde cholangiopancreatography (ERCP).*
Trial (Location) Sample Size Randomization NSAID, Time of Administration
Murray et al25 (Scotland) 220 Blocks of 20 Diclofenac 100 mg PR, immediately after ERCP
Khoshbaten et al 26 (Iran) 100 Blocks of 20 Diclofenac 100 mg PR, immediately after ERCP
Cheon et al 27 (United States) 207 Computer-generated Diclofenac 100 mgt PO, 30-90 minutes before
randomized set and 4-6 hours after ERCP
of numbers
Sotoudehmanesh et al28 (Iran) 442 Block randomization Indomethacin 100 mg PR, immediately before
with a balanced number ERCP
*Withdrawals were clearly reported for each study. The Jadad score of each study was 5.
tTotal dose.
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OR (95% GI)
0.37 (0.15-0.94)
0.12 (0.03-0.56)
0.97 (0.46-2.02)
0.45 (0.18-1.12)
0.44 (0.21-0.93)
5
OR (95% GI)
Figure 2. Forest plot illustrating results of a meta-analysis comparing NSAIDs with pla-
cebo in terms of pancreatitis after endoscopic retrograde cholangiopancreatog-
raphy. OR = odds ratio.
100-mg rectal suppository or placebo immediately before ERCP. Of 442 patients,
PEP developed in 22 (5%) (7 in the indomethacin group and 15 in the placebo group;
P = NS). The authors also reported that in a subgroup of patients with pancreatic duct
injection (a high-risk factor), the rate of PEP was significantly lower in the indo-
methacin group (1/44 [2%}) than in the placebo group (8/43 [l9%}) (P = 0.01).
It has been widely accepted that the mechanism of action of NSAIDs is the inhibi-
tion of prostaglandin synthesis. However, the exact role of prostaglandins in acute
pancreatitis is unclear. NSAIDs have anti-inflammatory mechanisms of action other
than the inhibition of prostaglandin synthesisY They have been found to be potent
inhibitors of phospholipase-2 activity in the serum of patients with acute pancreatitis
when tested in vitro. 38 NSAIDs have also been found to have beneficial effects in a
murine model of acute pancreatitis. 39
NSAIDs are inexpensive, easily administered, generally well tolerated, and admin-
istered as a single dose without the need for an intravenous infusion.3
The 4 studies in the present meta-analysis used different routes of drug adminis-
tration and found different Tmax values (~2 hours for oral vs ~30 minutes for rectal),
but these time differences are probably not clinically significant. The Tmax of
indomethacin suppositories is ~30 to 90 minutes after insertion, and, similar to
diclofenac, bioavailability is complete. 28
The present review included data from 4 high-quality RCTs2s-28 to assess the effec-
tiveness and tolerability of NSAIDs in the prophylaxis of post-ERCP pancreatitis. We
found that the prevalence of PEP in low-risk patients was significantly associated with
the prophylactic use of NSAIDs, whereas PEP in high-risk patients, mild PEP, and
moderate to severe PEP were not. Although serious gastrointestinal adverse events, such
as bleeding and ulceration, may occur with long-term NSAID use, they were not re-
ported after the administration of 1 or 2 doses in these 4 RCTs in the present
analysis. 2s - 28 Therefore, we believe that NSAIDs are well tolerated in the short term in
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sMild post-ERCP pancreatitis
Murray et al25 0.43 (0.17-1.10)
Cheon et al 27 1.08 (0.44-2.66)
Sotoudehmanesh et al28 0.69 (0.26-1.85)
Subtotal - 0.69 (0.40-1.17)-
Moderate to severe post-ERCP
pancreatitis
Murray et al25 0.20 (0.01-4.14)
Cheon et al 27 0.97 (0.06-15.74)
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Subtotal 0.22 (0.05-1.01)
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Figure 3. Forest plot illustrating results of meta-analysis comparing NSAIDs with placebo in terms of mild or moderate to severe
pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP). OR = odds ratio.
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Figure 4. Forest plot illustrating results of a meta-analysis comparing NSAIDs with placebo in terms of pancreatitis after endo-
scopic retrograde cholangiopancreatography in high-risk patients. OR = odds ratio.
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Figure 5. Forest plot illustrating results of a meta-analysis comparing NSAIDs with placebo in terms of pancreatitis after endo-
scopic retrograde cholangiopancreatography in low-risk patients. OR = odds ratio.
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Figure 6. Funnel plot illustrating a meta-analysis of the incidence of pancreatitis after
endoscopic retrograde cholangiopancreatography. log OR = logarithmic odds
ratio.
the prevention of PEP. Assessment of the quality of these RCTs according to the ]adad
scale30 found that all 4 trials were of high quality. Based on these findings, NSAIDs can
be considered effective and well tolerated in the prophylaxis of PEP.
Physicians should use prudent judgment in selecting patients with appropriate
indications for ERCP. Prophylactic pancreatic stent placement is the first line of PEP
prevention in high-risk cases. s Large-scale, multicenter, double-blind, RCTs are
needed to assess the efficacy of NSAIDs for the prevention of PEP in low- and high-
risk patients. Further studies to assess the efficacy of other anti-inflammatory agents
or combinations of drugs with various mechanisms of inflammatory pathways would
also be of interest.
CONCLUSION
Based on the findings from the present systematic review of 4 RCTs, NSAIDs were
effective and well tolerated in the prevention of PEP, especially in low-risk patients.
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